Pembrolizumab combined with lenvatinib as non-first-line therapy in patients with refractory biliary tract carcinoma-Reference-Cited by-同舟云学术

Pembrolizumab combined with lenvatinib as non-first-line therapy in patients with refractory biliary tract carcinoma

Published:2020-08 Issue:4 Volume:9 Page:414-424
ISSN:2304-3881
Container-title:Hepatobiliary Surgery and Nutrition
language:
Short-container-title:Hepatobiliary Surg Nutr

Author:

Lin Jianzhen,Yang Xu,Long Junyu,Zhao Songhui,Mao Jinzhu,Wang Dongxu,Bai Yi,Bian Jin,Zhang Lei,Yang Xiaobo,Wang Anqiang,Xie Fucun,Shi Weiwei,Yang Huayu,Pan Jie,Hu Ke,Guan Mei,Zhao Lin,Huo Li,Mao Yilei,Sang Xinting,Wang Kai,Zhao Haitao

Publisher

AME Publishing Company

Subject

General Medicine

Link

http://hbsn.amegroups.com/article/download/43240/pdf

Cited by 111 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anatomical classification of advanced biliary tract cancer predicts programmed cell death protein 1 blockade efficacy;Frontiers in Pharmacology;2024-08-30

2. Recent Advances in Immunotherapy for Advanced Biliary Tract Cancer;Current Treatment Options in Oncology;2024-07-27

3. Focusing on the Immune Cells: Recent Advances in Immunotherapy for Biliary Tract Cancer;Cancer Management and Research;2024-07

4. Real-world outcomes of chemotherapy plus immune checkpoint inhibitors versus chemotherapy alone in advanced, unresectable, and recurrent intrahepatic cholangiocarcinoma;Frontiers in Immunology;2024-05-23

5. Conversion surgery intervention versus continued systemic therapy in patients with a response after PD-1/PD-L1 inhibitor-based combination therapy for initially unresectable biliary tract cancer: a retrospective cohort study;International Journal of Surgery;2024-05-03